NCT02601950 2025-06-22A Study of Tazemetostat in Adult Participants With Soft Tissue SarcomaIpsenPhase 2 Completed267 enrolled 25 charts 2 FDA
NCT03213665 2025-01-27Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)National Cancer Institute (NCI)Phase 2 Completed20 enrolled 12 charts
NCT03456726 2022-12-16Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene MutationEisai Inc.Phase 2 Completed20 enrolled 17 charts
NCT02860286 2021-04-09Study of the EZH2 Inhibitor Tazemetostat in Malignant MesotheliomaEpizyme, Inc.Phase 2 Completed74 enrolled 23 charts